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Abstract: Glucose- and temperature-sensitive polymers of a phenylboronic acid derivative and 
diethylene glycol dimethacrylate (poly(3-acrylamidophenyl boronic acid-b-diethylene glycol 
methyl ether methacrylate); p(AAPBA-b-DEGMA)) were prepared by reversible addition–
fragmentation chain transfer polymerization. Successful polymerization was evidenced by 1H 
nuclear magnetic resonance and infrared spectroscopy, and the polymers were further explored 
in terms of their glass transition temperatures and by gel permeation chromatography (GPC). 
The materials were found to be temperature sensitive, with lower critical solution temperatures 
in the region of 12°C–47°C depending on the monomer ratio used for reaction. The polymers 
could be self-assembled into nanoparticles (NPs), and the zeta potential and size of these 
particles were determined as a function of temperature and glucose concentration. Subsequently, 
the optimum NP formulation was loaded with insulin, and the drug release was studied. We 
found that insulin was easily encapsulated into the p(AAPBA-b-DEGMA) NPs, with a load-
ing capacity of ~15% and encapsulation efficiency of ~70%. Insulin release could be regulated 
by changes in temperature and glucose concentration. Furthermore, the NPs were non-toxic 
both in vitro and in vivo. Finally, the efficacy of the formulations at managing blood glucose 
levels in a murine hyperglycemic diabetes model was studied. The insulin-loaded NPs could 
reduce blood glucose levels over an extended period of 48 h. Since they are both temperature 
and glucose sensitive and offer a sustained-release profile, these systems may comprise potent 
new formulations for insulin delivery.
Keywords: diethylene glycol methyl ether methacrylate, 3-acrylamidophenylboronic acid, 
nanoparticle, thermosensitive, glucose sensitive, insulin delivery
Introduction
Diabetes is a highly prevalent chronic metabolic disease in which the body is unable 
to regulate effectively the concentration of glucose in the blood.1,2 It is at present one 
of the three major conditions that endanger human health (the others being cancer 
and cardiovascular disease).3 Over the past 20 years, the incidence of diabetes has 
increased sharply.4 The development of new and more effective treatment regimens 
is hence urgent.
In the clinic, insulin is very widely used as an efficient and low-cost intervention 
for diabetes.5,6 Unfortunately, being a biologic drug it is liable to undergo degradation 
and/or aggregation during formulation, which markedly reduces efficacy owing to the 
importance of tertiary structure. Although insulin can be administered through both 
injection and non-injection routes, the latter generally suffer from low bioavailability.7,8 
However, daily administration of insulin by injection is uncomfortable for patients 
and can even be dangerous: the injection of excess insulin can result in serious shock 
responses such as hypoglycemia, syncope, or even death.9,10 To ameliorate these 
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issues, much effort has been invested in the development of 
smart drug delivery systems that are able to release insulin 
in response to changes in the blood glucose level.
A significant number of reports of glucose-sensitive 
systems have emerged in the literature over the last decade 
or so.11–13 There are three main classes of glucose-responsive 
materials: concanavalin, glucose oxidase, and phenylboronic 
acid (PBA). Concanavalin and glucose oxidase are proteins 
and thus have some shortcomings in terms of high cost, 
instability, and antigenicity.14 In contrast, PBA has none of 
those disadvantages and has been widely studied.15,16 A dia-
gram showing the reaction between PBA and glucose can be 
seen in the Supplementary materials, Scheme S1. Polymers 
based on PBA retain this glucose sensitivity; further, they 
generally possess high stability and can be structurally very 
versatile, and thus can be used to develop a broad range of 
systems.17,18 Unfortunately, glucose-sensitive PBA polymers 
face a number of challenges, including having shown some 
cytotoxicity. The pKa of PBA (~9.0) is much higher than the 
physiological pH, and thus, in the body, a PBA homopolymer 
is largely unionized.18 This renders it insoluble, and therefore 
it has only a minimal interaction with glucose in solution, 
limiting its ability to respond to changes in the concentration 
of the latter.
Researchers have adopted a range of approaches to 
overcome these drawbacks of PBA.19,20 One is to prepare 
polymers combining PBA with other monomers: this can 
result in polymers with more suitable pKa values (from 7.4 
to 9.0) and better able to respond to glucose under physi-
ological conditions.21 Polymers based on PBA can be used 
to make microparticles and hydrogels that can be loaded 
with insulin. For instance, Zhao et al22 prepared a new PBA-
based glucose-responsive nanogel. They found that insulin 
could effectively be loaded into the gel, and insulin release 
was triggered by the presence of glucose. In addition, Sun 
et al23 reported poly(N-isopropylacrylamide-co-3-acryl-
amidophenylboronic acid-co-dextran-maleic acid)-coated 
silica nanoparticles (NPs) loaded with insulin, and found 
the cumulative release of insulin in vitro to be dependent on 
glucose concentration.
The administration of insulin can cause problems in 
that the body temperature tends to rise upon its administra-
tion, because it triggers the burning of “brown fat” cells.24 
Diabetic patients are more likely to have a fever than those 
not suffering from this condition,25 and this increase in 
body temperature can be an issue because it triggers a loss 
of appetite.26 To counteract this, patients must reduce the 
amount of insulin injected or there is a risk of hypoglycemia. 
Controlling the insulin levels in the body through injection 
is thus challenging, and a dynamic drug delivery system 
able to respond to temperature and glucose would be highly 
desirable. There are some studies23 that report this in the 
literature (~10 articles), but there remains much more to be 
done given the potential of such materials to improve patient 
health and well-being. To impart thermoresponsive behavior, 
several authors have combined PBA with thermosensitive 
blocks in copolymers.27,28
Thermoresponsive polymers undergo a temperature-driven 
chain-to-globule transition and may be generally described 
by two threshold temperatures. They are water soluble either 
above an upper critical solution temperature (UCST) or below 
a lower critical solution temperature (LCST).29 LCST poly-
mers can self-assemble into micelles above the LCST. These 
micelles will then dissociate into aqueous solution when the 
temperature is lowered beneath the LCST. There are a range 
of moieties that can be used to provide such behavior. One 
commonly explored material is diethylene glycol methyl 
ether methacrylate (DEGMA), homopolymers of which are 
both thermoresponsive and biocompatible. A range of drug 
delivery systems based on DEGMA have been reported, 
including micelles, hydrogels, NPs, and hybrid particles.30,31 
Poly(DEGMA) exhibits an LCST between 22 and 27°C,32 
but this can be tuned by copolymerization.
In this work, a series of novel glucose- and temperature-
sensitive copolymers of DEGMA and the PBA derivative 
3-acrylamidophenylboronic acid (AAPBA) were prepared for 
the first time. These were generated by reversible addition–
fragmentation chain transfer polymerization. NPs of this 
polymer were prepared following the method reported by 
Chai et al33 and fully characterized. The particles were loaded 
with insulin, the loading efficiency was quantified, and the 
insulin release profile was determined in vitro. The toxicol-
ogy of the NP systems was examined both in vitro and in 
vivo. Finally, the therapeutic effects of the formulations were 
assessed using a murine model of diabetes.
Materials and methods
Materials
AAPBA was purchased from the Beijing Pure Chem. Co., 
Ltd. (Beijing, China) and DEGMA (98%) and S-1-dodecyl-
S′-(α,α′,-dimethyl-α″-acetic acid) trithiocarbonate (DDATC) 
from Sigma-Aldrich (Shanghai, China). Dimethyl forma-
mide (DMF) and 2,2-azo-bis-isobutyronitrile (AIBN; 97%) 
were procured from the Sinopharm Chemical Reagent Co., 
Ltd. (Shanghai, China); the latter was purified by recrys-
tallization from a 5% w/v solution in water before use. 
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Dimethyl sulfoxide (DMSO) was sourced from the China 
National Medicines Corporation Ltd. (Beijing, China). 
Insulin with a nominal activity of 28 IU/mg was obtained 
from the Xuzhou Wanbang Biochemical Co., Ltd. (Jiangsu, 
China). All solvents used in this work were of analytical grade 
and were dried by storing over activated 4 Å molecular sieves 
for 24 h prior to use. Water was triple distilled before use.
Polymer synthesis
Poly(3-acrylamidophenylboronic acid) (p(aaPBa))
p(AAPBA) was synthesized by reversible addition– 
fragmentation chain transfer (RAFT) polymerization using a 
method previously reported.34 This used AAPBA (1,000 mg) 
as the monomer, DDATC (10 mg) as the RAFT agent, AIBN 
(1 mg) as the initiator, and DMF (1 mL) as the solvent. This 
mixture was placed into a 25 mL reaction tube, sealed, and 
purged with nitrogen for 30 min. The tube was transferred to an 
oil bath preheated to 70°C, where it was left for 12 h. The prod-
uct was then recovered by rapid cooling in ice water for 5 min. 
p(AAPBA) was obtained by precipitating into diethyl ether, 
washing with acetone, and drying under vacuum for 75 h.
Poly(3-acrylamidophenylboronic acid-block-
diethylene glycol methyl ether methacrylate) 
(p(aaPBa-b-DegMa))
RAFT copolymerization was performed using p(AAPBA) as 
a macro RAFT agent, together with DEGMA as an additional 
monomer and AIBN (1 mg) as the initiator. These were dis-
solved in DMF (1 mL). As before, the mixture was sealed in 
a 25 mL reaction tube, purged with nitrogen for 30 min, and 
heated at 70°C for 12 h in an oil bath. The reaction was then 
quenched by immediate cooling in ice water for 5 min, and 
the product polymers obtained after precipitation into diethyl 
ether, washing with acetone, and drying under vacuum. By 
changing the ratio of p(AAPBA) to DEGMA, five polymers 
were prepared, as detailed in Table 1.
Polymer characterization
1H nuclear magnetic resonance (1H NMR) spectra were 
recorded at 24°C using a Unity-plus 400 NMR spectrometer 
(Varian, Palo Alto, CA, USA). Infrared (IR) spectra were col-
lected on an FTS-6000 instrument (Bio-Rad Co., Hercules, 
CA, USA) using the KBr tablet method (sample:KBr mass 
ratio 1:100). Measurements were taken over the range of 
500–4,000 cm−1 at a resolution of 2 cm−1. Thermogravimetric 
(TG) analysis was conducted under a flow of nitrogen using 
an STA 409PC analyzer (Netzsch, Selb, Germany), at a 
heating rate of 10°C⋅min−1.
The molecular weights (Mw and Mn) and molecular 
weight distributions of the polymers were determined by 
gel permeation chromatography (GPC) measurements on 
a Waters LS system (Waters LLC, Milford, MA, USA). 
Tetrahydrofuran (THF) was used as the eluent, at a flow rate 
of 1.0 mL⋅min−1, with a column temperature of 35°C.
The LCSTs of the polymers were determined using 
a UV-vis spectrophotometer (Lambda 35; Perkin Elmer, 
Waltham, MA, USA) fitted with a thermostatically controlled 
cuvette. Measurements were undertaken at a heating rate of 
0.5°C⋅min−1. The absorbance at 500 nm of aqueous solutions 
of each polymer (1.0 mg⋅mL−1) was recorded at different 
temperatures. The LCST was defined as the temperature 
corresponding to 50% of the maximum absorbance.
Preparation of NPs
p(AAPBA-b-DEGMA) NPs were prepared according 
to a previously reported method.33–35 A total of 10 mg of 
p(AAPBA-b-DEGMA) was dissolved in 2 mL of a mixed 
solvent system comprising DMSO and water (1:1 v/v), and 
20 mL of water was added to the resultant solution under 
stirring (600 rpm). After 3 h, the suspension obtained was 
centrifuged at 12,000 rpm for 10 min and dispersed into water 
(10 mL), followed by transfer to a dialysis tube (molecular 
weight cutoff [MWCO] 6000 Da) and dialysis against water 
for 72 h (at room temperature). The organic solvent was 
removed by replacing the water every 4 h during the dialysis 
process. Subsequently, the materials were placed in a −80°C 
freezer for 12 h and then freeze-dried at −45°C (SJIA-10N 
instrument; Ningbo Dual Ka Instrument Co., Ltd. Ningbo, 
China) to yield blank polymer NPs.
Insulin-loaded p(AAPBA-b-DEGMA) NPs were pre-
pared in a manner very similar to that used for blank NPs. 
As before, p(AAPBA-b-DEGMA) was dissolved in 2 mL of 
DMSO/water (1:1 v/v) to which was added 20 mL of an aque-
ous insulin solution under stirring (600 rpm). NP recovery 
and dialysis were then performed as for the blank NPs. The 
Table 1 The compositions of the amphiphilic copolymers produced
Sample ID Monomer:RAFT agent ratio
DEGMA:p(AAPBA) (mol/mol)
Yield (wt%)a
PaD-50-1 100:2 (454 mg:9.6 mg) 82.4
PaD-20-1 100:5 (454 mg:24 mg) 79.6
PaD-10-1 100:10 (454 mg:48 mg) 75.5
PaD-5-1 100:20 (454 mg:96 mg) 74.2
PaD-2-1 100:50 (454 mg:242 mg) 72.5
Notes: aYield was calculated via the weight method: Yield (wt%) =100× [mass of 
p(aaPBa-b-DegMa)]/[mass of DegMa + mass of p(aaPBa)]. PaD-X-Y, p(aaPBa-
b-DegMa) with DegMa:paaPBa molar ratios of X:Y.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; p(aaPBa), 
poly(3-acrylamidophenylboronic acid); raFT, reversible addition–fragmentation 
chain transfer.
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amount of free insulin in the supernatant was quantified by 
the Bradford method using a UV spectrometer (UV-1800; 
SHJH Company, Shanghai, China) at 595 nm.
The insulin encapsulation efficiency (EE) and load-
ing capacity (LC) were calculated using the following 
equations:
 
EE
Total insulin mass Mass of free insulin
Total insulin ma
= −
ss
×100
 
 
LC
Total insulin mass Mass of free insulin
NP mass
= − ×100
 
NP characterization
Transmission electron microscopy (TEM) images were 
obtained using a JEM-2100 microscope (JEOL, Tokyo, 
Japan). Samples were prepared by casting an aqueous sus-
pension of p(AAPBA-b-DEGMA) NPs (1 mg⋅mL−1) onto a 
copper grid covered with a thin film of formvar and carbon 
at 38°C. Zeta potential values were determined with a submi-
cron particle size analyzer (ZetaPALS/90plus; Brookhaven 
Instruments Corporation, Holtsville, NY, USA).
NP responsiveness to stimuli
The blank p(AAPBA-b-DEGMA) NPs were evaluated for their 
pH, temperature, and glucose sensitivity following the methods 
used in a previous report.33 The pH sensitivity was assessed 
by placing the NPs (4 mg) in phosphate-buffered saline (PBS; 
0.1 M, 10 mL) at pH 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, or 8.5 and 
determining their size by dynamic light scattering (DLS). Mea-
surements were undertaken at 37°C using a Zetasizer Nano S 
Instrument (Malvern Instruments, Malvern, UK). Temperature 
sensitivity was studied in PBS (0.1 M, pH 7.4; NP concentra-
tion 0.4 mg⋅mL−1) by DLS quantification of the NP sizes at 
12, 17, 22, 27, 32, 37, 42, and 47°C. Glucose sensitivity was 
explored by treating the blank NPs (4 mg) with glucose solu-
tions (0, 1, 2, and 3 mg⋅mL−1) in PBS (pH 7.4, 0.1 M, 10 mL) 
for 0, 10, 20, 30, 40, 50, and 60 min at 22°C. The sizes of the 
NPs were subsequently measured by DLS.
In vitro release behavior
The in vitro release of the different insulin-loaded NPs 
was investigated according to a previously reported meth-
od.36 Insulin-loaded NPs (5 mg) were placed in 20 mL of 
a glucose solution in PBS (0.1 M, pH 7.4). Four different 
solutions with varied glucose concentrations (0, 1, 2, and 
3 mg⋅mL−1) were employed. Release was measured under 
shaking (100 rpm) at 37°C. At predetermined times, 1 mL 
of supernatant was withdrawn, and the same volume of 
fresh pre-heated solution was added. The amount of free 
insulin was monitored using UV spectroscopy. Experiments 
were performed in triplicate, and the results are reported as 
mean ± standard deviation.
Toxicity
cell viability assays
Cell viability was undertaken following a method similar 
to that used in the literature37 using NIH 3T3 cells (a non-
cancerous mouse embryonic fibroblast cell line). The cell line 
was maintained in an incubator at 37°C with a 5% CO
2
 atmo-
sphere. Cells were grown in Dulbecco’s Modified Eagle’s 
Medium (DMEM; Gibco, New York, NY, USA) supple-
mented with 10% v/v fetal calf serum, 1% v/v non-essential 
amino acid solution, and 1% v/v penicillin/streptomycin 
solution (“complete DMEM”). Cells were seeded into 96-well 
plates at 10,000 cells per well (200 µL) and incubated for 
24 h. One hundred microliters of a copolymer NP  suspension 
(with concentrations ranging from 25 to 125 µg⋅mL−1) was 
then added to each well of the plates. After 24 h, the culture 
medium was removed and 20 µL of a solution of the MTT 
reagent in DMEM and 180 µL of complete DMEM were 
added to each well before the cells were incubated for a fur-
ther 4 h. Subsequently, all the liquid medium was removed 
from each well and 100 µL of DMSO added to dissolve the 
formazan crystals that had formed. The plates were shaken at 
low speed for 10 min, after which the absorbance was quanti-
fied on a microplate reader (Multiskan Spectrum; Thermo 
Fisher Scientific, Waltham, MA, USA) at 570 nm. The cell 
viability was determined relative to a negative control of 
untreated cells (set to have 100% viability).
In vivo toxicity studies
All animal experimental procedures were undertaken in 
accordance with the Guidelines for the Care and Use of Labo-
ratory Animals of the US National Institutes of Health (NIH 
Publication No 8523, revised 1985). Animals were procured 
from the Center of Laboratory Animal Science of Kunming 
Medical University. Ethical approval for all experiments 
was obtained from the Animal Care and Use Committee of 
Kunming Medical University (certificate number: KMMU 
2014002) prior to in vivo work beginning.
A total of 24 Kunming mice (12 males and 12 females) 
weighing 19–23 g were randomly divided into four groups 
of six mice each: three treatment groups and an untreated 
control group. The treatment groups were given 10, 20, or 
40 mg⋅kg−1⋅d−1 of p(AAPBA-b-DEGMA) by intraperitoneal 
(IP) injection (1 mL⋅kg−1⋅d−1). The control mice were given 
1 mL⋅kg−1⋅d−1 of saline solution by IP injection. After 60 days, 
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the mice were sacrificed and their blood was collected. 
Their red blood cell counts (RBCs), white blood cell counts 
(WBCs), serum protein, hematocrit, platelet, hemoglobin, 
serum creatinine, serum glutathione, total cholesterol, 
glucose, uric acid, alanine aminotransferase (ALT), and 
aspartate transaminase (AST) levels were quantified using 
an automated Olympus AU5400 biochemistry analyzer 
(Olympus, Tokyo, Japan). The livers, kidneys, spleens, 
hearts, and lungs of the sacrificed mice were collected for 
hematoxylin–eosin (HE) staining.
In vivo hypoglycemic experiments
Again, all animal experimental procedures were undertaken 
in accordance with the Guidelines for the Care and Use of 
Laboratory Animals of the US National Institutes of Health. 
Ethical approval for all experiments was obtained from the 
Animal Care and Use Committee of Kunming Medical 
University (certificate number: KMMU 2014002) prior to 
in vivo work beginning.
A total of 24 diabetes mellitus Kunming mice were 
kindly provided by Kunming Medical University. The fast-
ing blood glucose level of each mouse was 15.6 mmol⋅L−1 
at the start of the experiment, and they were randomly 
divided into a diabetes mellitus group, insulin injection 
group, and a p(AAPBA-b-DEGMA) NP treatment group. 
In addition, six healthy mice were used as a control group. 
The p(AAPBA-b-DEGMA) group received insulin-loaded 
PAD-5-1 NPs by a single IP injection (2.14 mg⋅kg−1; 0.4 mg 
insulin⋅kg−1). The insulin injection group was given a total 
of 0.4 mg⋅kg−1 of insulin in the 60 h experimental period. 
This was divided into two doses of 0.16 mg⋅kg−1 and a third 
dose of 0.08 mg⋅kg−1, given on days 1, 2, and 3, respectively. 
Each insulin dose was dissolved into 1 mL of normal saline 
for injection. The diabetes mellitus group was injected 
with 1 mL⋅kg−1 of saline solution IP. The control group 
animals were untreated. Blood was collected from the tail 
vein (50 µL) periodically, and a glucose meter (Accu-Chek 
Performa; Roche, Basel, Switzerland) was used to quantify 
blood glucose.
Results
Polymer synthesis and characterization
p(AAPBA-b-DEGMA) (PAD) glycopolymers were syn-
thesized via a sequential RAFT polymerization method 
(Scheme S2, Supplementary materials) with good yields 
(Table 1). Figure 1 shows the IR spectra of AAPBA, 
DEGMA, p(AAPBA), and PAD-5-1. AAPBA shows a 
number of characteristic absorption bands: a C=O stretch 
(1,660 cm−1), C=C stretch (1,640 cm−1), O–B–O bend 
(1,352 cm−1), and B–O stretch (1,014 cm−1). Vibrations from 
the benzene ring are present at 1,555 to 1,610 cm−1 and the 
acrylamide group at 698 and 791 cm−1. DEGMA shows a 
C=O stretch at 1,700 cm−1 and a C=C stretch at 1,650 cm−1. 
In the spectra of p(AAPBA) and PAD-5-1 (shown as an 
exemplar copolymer), the absorptions due to C=C groups 
disappear, indicating that successful polymerization had 
occurred. Analogous observations were made for the other 
PAD systems. The Fourier transform infrared spectroscopy 
(FTIR) spectra of all the copolymers contain the B–O stretch 
at 996 cm−1, which proved that AAPBA was incorporated into 
the polymer. The complete set of IR spectra can be found in 
the Supplementary materials, Figure S1. These findings are 
fully consistent with other reports.37,38
Figure 2 depicts the 1H NMR spectra of DEGMA, AAPBA, 
p(AAPBA), and PAD-5-1. The spectrum of DEGMA 
(Figure 2A) can be assigned as follows (D
2
O): δ 6.05 (1H, 
H1), 5.65 (1H, H2), 4.25 (2H, H3), 3.71 (2H, H4), 3.62 (2H, 
H5), 3.46 (2H, H6), 3.24 (3H, H7), and 1.79 (3H, H8). That 
of AAPBA (Figure 2B) contains the following resonances 
(DMSO-d6): δ 10.09 (1H, H4), 8.10–7.25 (phenyl H), 6.47 
(1H, H2), 6.20 (1H, H3), and 5.75 (2H, H1). The spectrum 
of p(AAPBA) (Figure 2C; NaOD/D
2
O, pH 9.5) has peaks 
at δ of 8.40–6.33 (phenyl H), 2.95 (2H, H10), 2.14 (1H, 
H4), 1.75 (1H, H9), 0.50–1.25 and 2.33 (C
12
H
25
 group, H1, 
H2, and H3). The copolymers, exemplified by PAD-5-1 in 
Figure 2D, all show analogous features. The signals in the 
PAD-5-1 spectrum (NaOD/D
2
O, pH 9.5) are assigned as fol-
lows: δ 8.10–7.15 (phenyl H), 3.60 (1H, H7), 3.42 (2H, H6), 
2.90 (1H, H5), 2.75 (1H, H4), and 1.78 (2H, H3).
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Figure 1 FT-Ir spectra of aaPBa, DegMa, p(aaPBa), and PaD-5-1.
Note: PaD-5-1, p(aaPBa-b-DegMa) (paaPBa:DegMa =1:5).
Abbreviations: aaPBa, 3-acrylamidophenylboronic acid; DegMa, diethylene 
glycol methyl ether methacrylate; p(aaPBa), poly(3-acrylamidophenylboronic acid); 
FTIr, Fourier transform infrared spectroscopy.
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Figure 2 1h-NMr spectra of (A) DegMa, (B) aaPBa, (C) p(aaPBa), and (D) PaD-5-1.
Notes: PaD-5-1, p(aaPBa-b-DegMa) (paaPBa:DegMa =1:5). Peaks crossed through correspond to the solvents used for NMr.
Abbreviations: 1h-NMr, 1h nuclear magnetic resonance; aaPBa, 3-acrylamidophenylboronic acid; DegMa, diethylene glycol methyl ether methacrylate; p(aaPBa), 
poly(3-acrylamidophenylboronic acid).
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Comparing the spectra of the monomers AAPBA and 
DEGMA with those of the polymers, it is clear that peaks 
corresponding to the ethylene groups have disappeared in 
p(AAPBA) and PAD-5-1, confirming successful polymer-
ization. There are some small differences in these spectra 
from those in other reports.34–37 This manifests mainly in 
the protons of the benzene ring in p(AAPBA) and PAD-5-1, 
which are in slightly different positions. This can likely be 
attributed to the solvent systems used for NMR: p(AAPBA) 
and p(AAPBA-b-DEGMA) are very insoluble in water at 
neutral pH, and thus, an NaOD solution in NaOH was used 
as the solvent, resulting in some peak shifts. Nevertheless, 
it is clear that polymerization was successful. Similar results 
are found for all the PAD polymers generated; the additional 
NMR spectra are given in Figure S2.
TG and derivative thermogravimetric (DTG) curves for 
p(AAPBA) and PAD-5-1 are given in Figure 3, and the 
remaining data are presented in Figure S3 (Supplementary 
materials). p(AAPBA) displays three mass losses at ~66°C, 
360°C, and 412°C. PAD-5-1 has two mass losses at ~313°C 
and 386°C. For p(AAPBA), the first mass loss at 66°C is 
attributed to water adsorbed onto the polymer. The mass 
loss at 313–360°C corresponds to the thermal decomposition 
of pendent sugar residues.39,40 The last stage of mass loss is 
the thermal degradation of the backbone, which occurs at a 
lower temperature for PAD-5-1 than for p(AAPBA). These 
observations agree closely with the literature.34
The molecular weights of the polymers were determined 
by GPC and are summarized in Table 2. An increasing 
proportion of p(AAPBA) in the p(AAPBA-b-DEGMA) 
co-polymers leads to the Mw and Mn increasing, while the 
polydispersity index (PDI) is roughly constant. This agrees 
with a previous report for a vinylcaprolactam/AAPBA 
polymer.41
NP formation and characterization
Photographs of suspensions of the different p(AAPBA-b-
DEGMA) NPs are provided in Figure 4, along with TEM 
images. The polymer NPs all form stable suspensions in 
water and comprise submicron-sized spherical particles. The 
particles appear to increase in size with increasing amounts 
of p(AAPBA) in the polymer.
The key physicochemical properties of the NPs are sum-
marized in Table 3. The zeta potential of the NPs produced 
became increasingly negative as the p(AAPBA) content 
increased, in accordance with other work in the literature.42 
Figure 3 Thermal analysis of p(aaPBa) and PaD-5-1, showing (A) DTg and (B) Tg curves.
Note: PaD-5-1, p(aaPBa-b-DegMa) (paaPBa:DegMa =1:5).
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; DTg, derivative thermogravimetric; p(aaPBa), poly(3-acrylamidophenylboronic acid); Tg, 
thermogravimetric.
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Table 2 The molecular weights (Mw and Mn) and molecular weight 
distributions (PDI) of the copolymers prepared in this work
Sample DEGMA/p(AAPBA) 
molar ratio
Mw Mn PDI
PaD-50-1 100:2 86,454 74,792 1.16
PaD-20-1 100:5 99,436 86,742 1.15
PaD-10-1 100:10 101,438 88,489 1.15
PaD-5-1 100:20 106,562 94,838 1.12
PaD-2-1 100:50 107,651 92,546 1.16
Note: PaD-X-Y, p(aaPBa-b-DegMa) with DegMa:paaPBa molar ratios of X:Y.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; p(aaPBa), 
poly(3-acryl amidophenylboronic acid); PDI, polydispersity index.
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As a result, the NP suspensions should become more stable. 
In contrast, a reduced proportion of DEGMA raised the 
LCST. All the NPs have low PDIs, ranging from 0.09 to 
0.14, with no clear patterns in the data.
Figure 5 illustrates the changes in the NPs’ hydrodynamic 
diameters that arose following changes in temperature and 
pH values. AAPBA shows glucose sensitivity at high pH.13 
However, the inclusion of DEGMA in the copolymer is 
expected to decrease the pKa of AAPBA,16 and it is necessary 
to examine whether the co-polymers are glucose sensitive 
under physiological conditions. The results obtained after 
exposing the NPs to PBS at different pHs (Figure 5A) show 
that the diameters of PAD-50-1 and PAD-20-1 decrease 
in size by 22 nm and 14 nm, respectively, as the pH is 
increased from 5 to 9. In contrast, the diameters of PAD-10-1, 
PAD-5-1, and PAD-2-1 increase by 12, 36, and 44 nm. The 
temperature data (Figure 5B) for all the NPs reveal that the 
diameter declines with an increase in temperature. This is 
most pronounced for PAD-50-1, as a result of it having the 
highest DEGMA content.
PBA derivatives can react with 1,2- or 1,3-diol com-
pounds to form reversible five- or six-membered ring esters,43 
and thus, in general, PBA-based polymers have good glucose 
sensitivity.44,45 This was explored for the PAD polymers 
prepared in this work. The diameters of the NPs in glucose 
solutions of various concentrations are illustrated in Figure 6. 
It is clear that the PAD-50-1 and PAD-20-1 NPs undergo 
minimal change in size as the glucose concentration rises 
from 0 to 3 mg⋅mL−1, even after immersion for an hour. This 
is likely to be because there is little of the glucose-sensitive 
AAPBA monomer in these polymers. The hydrodynamic 
diameters of the NPs of PAD-10-1, PAD-5-1, and PAD-2-1 
increase gradually with the immersion time in glucose 
solution, however, showing them to have distinct glucose 
sensitivity. This increase in size becomes more profound 
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Figure 4 Images of the p(aaPBa-b-DegMa) NP suspensions (1) and TeM micro-
graphs of the dried NPs (2).
Notes: (A) PaD-50-1, (B) PaD-20-1, (C) PaD-10-1, (D) PaD-5-1, and (E) PaD-
2-1. PaD-X-Y, p(aaPBa-b-DegMa) with DegMa:paaPBa molar ratios of X:Y.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; NP, nano-
particle; p(aaPBa), poly(3-acrylamidophenylboronic acid); TeM, transmission electron 
microscopy.
Table 3 The lcsTs, zeta potentials, and polydispersity indices of 
the copolymer NPs
Samples DEGMA/p(AAPBA) 
molar ratio
Zeta potential 
(mV)
LCST 
(°C)
PDI
PaD-50-1 100:2 −21.4±2.3 32.0 0.14±0.04
PaD-20-1 100:5 −26.9±1.8 34.5 0.13±0.02
PaD-10-1 100:10 −33.6±1.7 36.5 0.09±0.01
PaD-5-1 100:20 −37.2±0.9 38.5 0.12±0.02
PaD-2-1 100:50 −40.3±1.2 42.5 0.11±0.03
Notes: PaD-X-Y, p(aaPBa-b-DegMa) with DegMa:paaPBa molar ratios of X:Y. 
Data are presented as mean ± standard deviation.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; lcsT, 
lower critical solution temperature; NP, nanoparticle; p(aaPBa), poly(3-acrylamido-
phenylboronic acid); PDI, polydispersity index.
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Figure 5 The hydrodynamic diameters of copolymer NPs at different (A) ph and (B) temperatures.
Note: PaD-X-Y, p(aaPBa-b-DegMa) with DegMa:paaPBa molar ratios of X:Y.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; NP, nanoparticle; p(aaPBa), poly(3-acrylamidophenylboronic acid); T, temperature.
as the glucose concentration is raised from 0 to 3 mg⋅mL−1. 
Concomitantly, the values of I/I
0
 (the light scattering intensity 
of the glucose-treated NP suspensions divided by the scat-
tering intensity of the particles without glucose treatment) 
decrease gradually as the glucose concentration increases.
The increase in hydrodynamic diameter was greatest in 
the 3 mg⋅mL−1 glucose solution in all cases, reflecting the 
ability of the particles to take up glucose and expand. With the 
greater p(AAPBA) content going from PAD-50-1 to PAD-
5-1, the hydrodynamic diameter increased more noticeably 
Figure 6 (Continued)
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with the rising glucose concentration. PAD-2-1 behaves 
very similarly to PAD-5-1, which might be because steric 
hindrance means that not all the AAPBA groups in PAD-2-1 
can react with the glucose present.
The stability of the NPs in aqueous solution was studied 
over 6 weeks (Figure S4A). No changes in size are seen, 
indicating that the p(AAPBA-b-DEGMA) NPs are stable in 
aqueous solution with no aggregation observed. The glucose 
sensitivity is found to be reversible (Figure S4B). All the NPs 
swelled after the first treatment with 3 mg⋅mL−1 glucose and 
then contracted back to their original size upon transfer to 
distilled water. When subsequently treated with a glucose 
solution, the NPs swell again.
Considering the earlier results, of the five different 
p(AAPBA-b-DEGMA) NPs, PAD-5-1 appeared to be the 
optimal system. PAD-5-1 and PAD-2-1 were the most 
glucose-sensitive materials, with both being very similar 
in this regard. PAD-5-1 was the more temperature sensitive 
Figure 6 changes in the size of the p(aaPBa-b-DegMa) NPs as a function of immersion time (t) in ph 7.4 PBs solutions of glucose.
Notes: (A) PaD-50-1; (B) PaD-20-1; (C) PaD-10-1; (D) PaD-5-1; and (E) PaD-2-1 are shown. The left images show the hydrodynamic diameters, while those on the right 
give I/I0 (the light scattering intensity of the glucose-treated NP suspensions divided by the scattering intensity of the particles without glucose treatment). I/I0 values reflected 
the extent of swelling. PaD-X-Y, p(aaPBa-b-DegMa) with DegMa:paaPBa molar ratios of X:Y.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; NP, nanoparticle; p(aaPBa), poly(3-acrylamidophenylboronic acid); PBs, phosphate-buffered saline.
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The drug release behavior of PAD-5-1 NPs loaded with 
the different insulin amounts (Table 4) was tested at different 
temperatures. Data for insulin loading (I-L)-4 are given in 
Figure 7, and the remaining data are presented in Figure S5 
(Supplementary materials). In general, insulin release is 
slower at higher temperatures, with the formulation with low-
est LC (I-L-1) showing the least sensitivity to temperature. 
The NPs are hence able to regulate their glucose release in 
response to changes in temperature.
The results suggest that if the body heats up as a result 
of insulin production, then the NPs will slow their release 
rate to counteract this change. Similarly, a reduction in 
body temperature will cause an increase in insulin release 
from the NPs. It should be noted that the temperature range 
explored is somewhat wider than physiological conditions, 
even in illness, but in extreme cases, the body temperature 
can exceed 40°C, and so, these experiments provide insight 
into how the systems would behave in conditions of high 
fever (more common in those with diabetes).
Drug release from I-L-4 was also explored in solutions 
of different glucose concentrations (see Figure 7B for data 
at 37°C). In all cases at 37°C, a burst of release is observed 
in the first hour, followed by sustained insulin release over 
at least the next 24 h. A plateau is seen after 36 h when the 
glucose concentration was 3 mg⋅mL−1 and a greater amount of 
insulin release obtained at higher glucose concentrations. This 
effect arises because as the glucose concentration is increased 
the NPs will swell, and as they do so, embedded insulin can 
diffuse out into solution. The glucose sensitivity is greatest at 
37°C (see Figure S6 for data recorded at other temperatures), 
and insulin release slows with increasing temperature. The 
percentage release values observed and the release rates are 
broadly in agreement with the literature.49–51
of these two materials (ie, had a lower LCST) and further, 
since AAPBA is very expensive, is more cost-effective 
than PAD-2-1. PAD-5-1 was thus taken forward into fur-
ther work.
Insulin loading and release
Insulin loading into a formulation is affected by hydrophobic 
and hydrophilic interactions, electrostatic interactions, and 
hydrogen bonding, inter alia.46 Since insulin contains amino 
acids, it can form stable complexes with the AAPBA sections 
of the PAD copolymers through these interactions,47 in 
accordance with other reports.48
PAD-5-1 was loaded with insulin using solutions of 
varied concentrations, and the results are summarized in 
Table 4. These data show that insulin was easily encapsulated 
into the PAD-5-1 NPs, with an LC of ~12%–19% and EE 
of ~67%–75%. Unsurprisingly, increasing the concentration 
of insulin in the solution used for loading leads to greater LCs 
but lower EEs. The loading observed in this work is higher 
than that in other reports: Guo et al34 reported an LC of ~10% 
and EE of ~60%, while Li et al39 obtained an LC of ~13%.
Table 4 Insulin lcs and ees of PaD-5-1 NPs
NP  
sample
Group Insulin concentration 
(mg⋅mL−1)
LC (%) EE (%)
PaD-5-1 I-l-1 0.25 12.4±3.2 75.1±9.2
I-l-2 0.50 13.2±2.9 74.2±7.4
I-l-3 0.75 16.7±3.1 72.4±8.4
I-l-4 1.00 18.7±2.9 70.1±8.3
I-l-5 1.25 19.2±3.7 66.7±9.7
Notes: PaD-5-1, p(aaPBa-b-DegMa) (paaPBa:DegMa =1:5). Data are presented 
as mean ± standard deviation.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; 
EE, encapsulation efficiency; I-L, insulin loading; LC, loading capacity; NP, nanoparticle; 
p(aaPBa), poly(3-acrylamidophenylboronic acid).
Figure 7 In vitro release of the insulin-loaded I-l-4 particles in PBs (ph 7.4) at different (A) temperatures and (B) glucose concentrations.
Note: I-l-4, insulin-loaded NPs prepared from a 1 mg⋅ml−1 insulin solution.
Abbreviations: NP, nanoparticle; PBs, phosphate-buffered saline.
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It is thus clear that the NPs prepared in this work are 
able to respond to both changes in glucose concentration and 
temperature. If used in the treatment of diabetes, they would 
therefore be able to regulate insulin levels in response to these 
stimuli, helping to ensure that patients do not run the risk 
of hypoglycemia. The mechanism proposed for the insulin 
loading and glucose-responsive nature of the materials is 
summarized in Scheme S3 in the Supplementary materials.
In vitro cytotoxicity and animal toxicity 
testing
The cytotoxicity of the different p(AAPBA-b-DEGMA) NPs 
on NIH 3T3 cells was determined using the MTT method. 
The cells were exposed to the NPs at final concentrations 
from 8.33 to 41.7 mg⋅mL−1, and the results are given in 
Figure 8. After incubating for 24 h, the relative cell viability 
was close to or higher than 100% of the negative control 
(untreated cells) in all cases, indicating that the presence of 
the glycopolymer did not negatively impact cell viability. 
There is perhaps a slight tendency for the cell viability to be 
higher with the polymers with the lowest AAPBA content, 
but this is not particularly marked. The photos of NIH 3T3 
cells in culture (Figure S7) show no changes in cell morphol-
ogy after exposure to the NPs.
Although a helpful initial experiment, the MTT method can-
not fully reflect the in vivo toxicity of the materials accurately, 
and hence following the promising results from MTT, it 
was necessary to conduct animal toxicity tests to determine 
Figure 8 cell viability as a function of the concentration of p(aaPBa-b-DegMa) 
NPs, as assessed using the MTT assay at 37°c after 24 h exposure.
Notes: The data are expressed as mean ± SD from five independent experiments, 
with three replicates per experiment. PaD-X-Y, p(aaPBa-b-DegMa) with 
DegMa:paaPBa molar ratios of X:Y. The concentration refers to the initial 
concentration of the NP suspension; the final concentration in culture is one-third 
of this value.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; NP, nano-
particle; p(aaPBa), poly(3-acrylamidophenylboronic acid); sD, standard deviation.
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whether the materials are safe in vivo. For animal toxicity, 
research has found that PBA has a certain level of toxicity: 
when given orally to rats, the LD
50
 is 740 mg⋅kg−1, and 
when applied to the abdominal cavity in mice, the LD
50
 is 
320 mg⋅kg−1.52,53 This toxicity is likely to be affected by the 
incorporation of PBA into a copolymer; in vivo toxicity results 
for PAD-5-1 are presented in Figure 9 and Table 5. HE stain-
ing images of the livers, kidneys, hearts, spleens, and lungs of 
mice given the PAD-5-1 NPs by IP injection (Figure 9) show 
no obvious signs of damage after the 60-day treatment period. 
A quantification of blood biochemical markers (Table 5) also 
showed no obvious changes from the negative control group, 
demonstrating that the materials had no toxicity in vivo.
In vivo hypoglycemic studies
To quantify glucose levels, the blood of diabetes mellitus 
mice was periodically taken from the tail vein for analysis. 
Before treatment, the mice in the negative control group were 
lively and active, while the diabetic mice were listless. After 
treatment, the behavior of the control and treatment groups 
was much more similar.
The glucose levels recorded (Figure 10) show that there 
were no significant changes in glucose level over 60 h for 
the control and diabetic groups. In contrast, the glucose level 
decreases rapidly over the first hour after injection for the 
PAD-5-1 NP group and insulin injection group. Our results 
agree well with previously reported studies in this regard.47,49,54 
The insulin-loaded NPs and injection-treated groups have very 
similar glucose levels from 0 to 48 h after treatment, but after 
48 h, the former showed an increase in blood glucose levels. 
This suggests that the NPs induce a stable hypoglycemic effect 
in the body over 48 h, but after this time, their efficacy is 
decreased. In future studies, we will seek to optimize the for-
mulations further to extend their duration of effectiveness.
A number of researchers have used insulin-loaded NPs 
for oral administration to mice or rats. Guo et al38 prepared 
a methacrylate and 3-acrylamidophenyl boronic acid-based 
amphiphilic glycopolymer and observed a significant decrease 
in blood glucose levels after oral administration. Other stud-
ies have also proven that orally administered NPs can effec-
tively lower blood sugar levels in animals, and our results 
are consistent with those reported by Zhang et al21 and Sun 
et al.55 An AAPBA nanogel has additionally been explored 
for nasal administration.47 However, treatment of diabetes 
via oral or nasal administration is problematic because the 
durations of hypoglycemic efficacy are low, as Guo et al38 
report – typically 12–24 h. Here, we find that we can at least 
double this time using our novel NPs and IP injection.
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Figure 9 representative he staining images (200× magnification) from the (A) liver, (B) lung, (C) spleen, (D) kidney, and (E) heart with images marked (1) denoting the 
negative control group, and the observation groups were given (2) 10, (3) 20, and (4) 40 mg⋅kg−1⋅d−1 of PaD-5-1 by IP injection.
Note: PaD-5-1, p(aaPBa-b-DegMa) (paaPBa:DegMa =1:5).
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; he, hematoxylin–eosin; IP, intraperitoneal; p(aaPBa), poly(3-acrylamidophenylboronic acid).
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Table 5 Blood biochemical markers measured after injection of the PaD-5-1 NPs into mice for 60 days (n=5, mean ± sD)
Marker (units) Control group Observation group (mg⋅kg−1⋅d−1)
10 20 40
rBc (×106 µl−1) 2.80±0.26 2.89±0.23 2.84±0.15 2.85±0.13
WBc (×103 µl−1) 9.54±0.31 9.44±0.62 9.38±0.16 9.29±0.43
hemoglobin (g⋅dl−1) 14.12±1.16 14.79±1.23 14.64±1.86 14.83±2.25
hematocrit (vol%) 35.92±1.17 36.73±1.57 35.85±2.27 36.01±1.85
Platelet (×103 µl−1) 89.07±3.17 90.15±2.15 91.33±2.59 90.36±2.76
serum protein (g⋅l−1) 56.02±3.12 54.63±3.62 56.82±2.21 57.56±2.82
serum creatinine (mg⋅dl−1) 3.47±0.19 3.47±0.21 3.54±0.38 3.52±0.45
serum glutathione (mg⋅dl−1) 0.64±0.11 0.61±0.10 0.60±0.16 0.59±0.12
Total cholesterol (mg⋅dl−1) 72.02±4.34 72.15±5.43 72.02±4.84 71.01±5.08
glucose (mg⋅dl−1) 262.31±10.13 253.35±9.12 250.39±8.17 246.58±9.92
Uric acid (mg⋅dl−1) 5.21±0.27 5.26±0.38 5.42±0.46 5.38±0.37
asT (U⋅l−1) 39.45±3.32 40.32±3.27 40.54±2.21 41.12±3.04
alT (U⋅l−1) 96.62±4.78 97.89±4.78 99.25±4.92 102.06±5.87
Note: PaD-5-1, p(aaPBa-b-DegMa) (paaPBa:DegMa =1:5).
Abbreviations: alT, alanine aminotransferase; asT, aspartate transaminase; DegMa, diethylene glycol methyl ether methacrylate; p(aaPBa), poly(3-
acrylamidophenylboronic acid); rBc, red blood cell count; sD, standard deviation; WBc, white blood cell count.
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Conclusion
In this study, a series of new amphiphilic block glycopo-
lymers based on PBA and diethylene glycol methyl ether 
methacrylate was synthesized. The Mw and Mn of the poly-
mers increase with the proportion of boronic acid in the reac-
tion mixture. The polymers could be assembled into stable 
spherical NPs, 50–250 nm in size, which exhibited glucose-
sensitive behavior at physiological pH. When the NPs were 
immersed in glucose solutions, the particle size increased 
with the glucose concentration. They were also thermo-
responsive, showing a distinct reduction in size when the 
temperature was increased through the LCST. Insulin could 
be encapsulated into the NPs, with an LC of ~12%–20%. The 
release of insulin was found to accelerate with an increase in 
the glucose concentration of the release milieu and to slow 
down with rising temperature. The biocompatibility of the 
polymers is very high, both in vitro and in vivo, indicating 
their potential for use in the biomedical fields. In addition, the 
polymer NPs were able to induce hypoglycemic effects in a 
murine model of diabetes, with efficacy maintained for 48 h. 
Overall, the data indicate that the glycopolymers developed 
in this work could be used as self-regulated insulin delivery 
systems in the future.
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Supplementary materials
Scheme S1 The reaction between PBa and glucose.
Abbreviation: PBa, phenylboronic acid.
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Scheme S2 The synthesis of p(aaPBa) and p(aaPBa-b-DegMa) by raFT polymerization.
Notes: (A) synthesis of p(aaPBa); (B) synthesis of p(aaPBa-b-DegMa).
Abbreviations: aIBN, 2,2-azo-bis-isobutyronitrile; DDaTc, s-1-dodecyl-s′-(α,α′,-dimethyl-α″-acetic acid) trithiocarbonate; DegMa, diethylene glycol methyl ether 
methacrylate; DMF, dimethyl formamide; p(aaPBa), poly(3-acrylamidophenylboronic acid); raFT, reversible addition–fragmentation chain transfer.
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Scheme S3 a schematic illustrating self-assembly of the block copolymers into nanoparticles in aqueous solution, with and without insulin and glucose.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; p(aaPBa), poly(3-acrylamidophenylboronic acid).
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Figure S1 Ir spectra of PaD-50-1, PaD-20-1, PaD-10-1, and PaD-2-1, recorded in the form of a KBr tablet (sample:KBr mass ratio 1:100).
Note: PaD-X-Y, p(aaPBa-b-DegMa) with DegMa:paaPBa molar ratios of X:Y.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; Ir, infrared; p(aaPBa), poly(3-acrylamidophenylboronic acid).
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Figure S2 1h-NMr spectra of PaD-50-1 (NaOD/D2O, ph 9.5), PaD-20-1 (NaOD/D2O, ph 9.5), PaD-10-1 (NaOD/D2O, ph 9.5), and PaD-2-1 (NaOD/D2O, ph 9.5).
Notes: Peaks crossed through correspond to the solvents used for NMr. PaD-X-Y, p(aaPBa-b-DegMa) with DegMa:paaPBa molar ratios of X:Y.
Abbreviations: 1h-NMr, 1h nuclear magnetic resonance; DegMa, diethylene glycol methyl ether methacrylate; p(aaPBa), poly(3-acrylamidophenylboronic acid).
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Figure S3 DTg (left) and Tg (right) data for PaD-50-1, PaD-20-1, PaD-10-1, and PaD-2-1.
Note: PaD-X-Y, p(aaPBa-b-DegMa) with DegMa:paaPBa molar ratios of X:Y.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; DTg, derivative thermogravimetric; p(aaPBa), poly(3-acrylamidophenylboronic acid); Tg, thermo-
gravimetric.
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Figure S4 (A) The stability of blank p(aaPBa-b-DegMa) NPs in ph 7.4 PBs and (B) their reversible glucose sensitivity.
Note: PaD-X-Y, p(aaPBa-b-DegMa) with DegMa:paaPBa molar ratios of X:Y.
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; NP, nanoparticle; p(aaPBa), poly(3-acrylamidophenylboronic acid); PBs, phosphate-buffered saline.
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Figure S5 In vitro release of insulin into ph 7.4 PBs at different temperatures for (A) I-l-1, (B) I-l-2, (C) I-l-3, and (D) I-l-5 insulin-loaded NPs.
Abbreviations: I-l, insulin loading; NP, nanoparticle; PBs, phosphate-buffered saline.
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Figure S6 In vitro release of insulin from I-l-4 into PBs (ph 7.4) at various glucose concentrations at (A) 25, (B) 38.5, and (C) 42°c.
Abbreviations: I-l, insulin loading; PBs, phosphate-buffered saline.
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Figure S7 Digital photographs (400× magnification) of NIH 3T3 cells after treatment with PAD-5-1 NPs.
Notes: (A) Untreated cells and cells treated with (B) 8.33, (C) 16.7, (D) 25, (E) 33.3, and (F) 41.7 µg⋅ml−1 of PaD-5-1. PaD-5-1, p(aaPBa-b-DegMa) (paaPBa:DegMa =1:5).
Abbreviations: DegMa, diethylene glycol methyl ether methacrylate; NP, nanoparticle; p(aaPBa), poly(3-acrylamidophenylboronic acid).
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